Aardvark Therapeutics, Inc. (AARD)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
4.76 USD
+0.05
(1.062%)
⇧
(Oct. 9, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:04 a.m. EDT
The investment case for Aardvark Therapeutics has collapsed due to a catastrophic clinical setback. The FDA hold on the late-stage ARD-101 program regarding cardiac safety concerns has triggered a 32% drop and a downgrade from major institutions like Morgan Stanley. Fundamentally, the company is in deep distress with negative earnings, negative free cash flow, and a deteriorating return on equity. The balance sheet, while currently showing low debt, is being eroded by significant operating losses. Technically, the stock is trading well below its 50-day and 200-day averages, confirming a strong downtrend. The options market reflects this fear perfectly, with traders pouring capital into put options to protect against further declines rather than betting on a recovery. With no dividend to provide income and a high-risk profile exacerbated by the halted trial, this is a clear avoid. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.139145 |
| AutoETS | 0.143990 |
| AutoARIMA | 0.144002 |
| AutoTheta | 0.162660 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 0.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.186 |
| Excess Kurtosis | -1.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.905 |
| Market Cap | 104,171,872 |
| Forward P/E | -2.00 |
| Website | https://aardvarktherapeutics.com |
As of Oct. 10, 2026, 6:04 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive volume in out-of-the-money puts (over 200 contracts at the $5 strike) compared to negligible call activity. While there is some speculative call flow at further strikes, the overwhelming sentiment is hedging against a continued decline, likely driven by the FDA hold on the lead drug candidate.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.67464113 |
| Address1 | 4,370 La Jolla Village Drive |
| Address2 | Suite 1050 |
| All Time High | 19.58 |
| All Time Low | 3.35 |
| Ask | 4.83 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 130,590 |
| Average Daily Volume3 Month | 146,392 |
| Average Volume | 146,392 |
| Average Volume10Days | 130,590 |
| Bid | 4.1 |
| Bid Size | 5 |
| Board Risk | 8 |
| Book Value | 3.418 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.76 |
| Current Ratio | 12.629 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,789,430,400 |
| Day High | 4.8 |
| Day Low | 4.6 |
| Debt To Equity | 0.905 |
| Display Name | Aardvark Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -73,913,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.478 |
| Enterprise Value | 35,355,836 |
| Eps Current Year | -3.1675 |
| Eps Forward | -2.38125 |
| Eps Trailing Twelve Months | -3.21 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.9605 |
| Fifty Day Average Change | -1.2004995 |
| Fifty Day Average Change Percent | -0.2014092 |
| Fifty Two Week Change Percent | -67.46411 |
| Fifty Two Week High | 16.6 |
| Fifty Two Week High Change | -11.84 |
| Fifty Two Week High Change Percent | -0.713253 |
| Fifty Two Week Low | 3.35 |
| Fifty Two Week Low Change | 1.4100003 |
| Fifty Two Week Low Change Percent | 0.42089564 |
| Fifty Two Week Range | 3.35 - 16.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,739,457,000,000 |
| Float Shares | 11,008,078 |
| Forward Eps | -2.38125 |
| Forward P E | -1.9989504 |
| Free Cashflow | -46,898,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 28 |
| Fullday Change | 0.05000019 |
| Fullday Change Percent | 1.0615752 |
| Fullday Price | 4.76 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15771 |
| Held Percent Institutions | 0.52604 |
| Implied Shares Outstanding | 21,884,846 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-02-13 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. |
| Long Name | Aardvark Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 104,171,872 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_614979892 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -69,889,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 121,679,743 |
| Number Of Analyst Opinions | 9 |
| Open | 4.61 |
| Operating Cashflow | -69,408,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Phone | 858 225 7696 |
| Previous Close | 4.71 |
| Price Eps Current Year | -1.5027624 |
| Price Hint | 4 |
| Price To Book | 1.3926274 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.566 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.25 |
| Region | US |
| Regular Market Change | 0.05000019 |
| Regular Market Change Percent | 1.0615752 |
| Regular Market Day High | 4.8 |
| Regular Market Day Low | 4.6 |
| Regular Market Day Range | 4.6 - 4.8 |
| Regular Market Open | 4.61 |
| Regular Market Previous Close | 4.71 |
| Regular Market Price | 4.76 |
| Regular Market Time | 1,791,576,001 |
| Regular Market Volume | 140,864 |
| Return On Assets | -0.4038 |
| Return On Equity | -0.66019994 |
| Sand P52 Week Change | 0.17383456 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 21,884,846 |
| Shares Percent Shares Out | 0.0194 |
| Shares Short | 424,912 |
| Shares Short Previous Month Date | 1,786,665,600 |
| Shares Short Prior Month | 611,764 |
| Short Name | Aardvark Therapeutics, Inc. |
| Short Percent Of Float | 0.029000001 |
| Short Ratio | 2.92 |
| Source Interval | 15 |
| State | CA |
| Symbol | AARD |
| Target High Price | 28.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 11.11111 |
| Target Median Price | 6.0 |
| Total Cash | 73,870,000 |
| Total Cash Per Share | 3.375 |
| Total Debt | 677,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.21 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.146725 |
| Two Hundred Day Average Change | -2.386725 |
| Two Hundred Day Average Change Percent | -0.33396065 |
| Type Disp | Equity |
| Volume | 140,864 |
| Website | https://aardvarktherapeutics.com |
| Zip | 92,122 |